Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus

Bibliographic Details
Main Authors:	Ji, Linong, Onishi, Yukiko, Ahn, Chul Woo, Agarwal, Pankaj, Chou, Chien‐Wen, Haber, Harry, Guerrettaz, Kelly, Boardman, Marilyn K
Format:	Online
Language:	English
Published:	Wiley-Blackwell 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019288/

Similar Items

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
by: Onishi, Yukiko, et al.
Published: (2012)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
by: Ridge, T, et al.
Published: (2012)

Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
by: Chiquette, Elaine, et al.
Published: (2012)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
by: Mathieu, Chantal, et al.
Published: (2013)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
by: Goud, Aditya, et al.
Published: (2015)

Onset of Glycemic and Weight Outcomes in Patients Initiating Exenatide Once Weekly: The Relationship of Exenatide Exposure with Efficacy over the First 24 Weeks of Treatment
by: Blevins, Thomas, et al.
Published: (2016)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
by: Henry, Robert R., et al.
Published: (2013)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
by: Simó, Rafael, et al.
Published: (2015)

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
by: Wysham, C, et al.
Published: (2011)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
by: Davies, Melanie, et al.
Published: (2013)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
by: Alshali, Khalid Z., et al.
Published: (2016)

The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
by: Wang, Bruce, et al.
Published: (2015)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders, William B, et al.
Published: (2016)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
by: Rosenstock, Julio, et al.
Published: (2013)

Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
by: Diamant, Michaela, et al.
Published: (2012)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
by: Tobin, G S, et al.
Published: (2012)

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study
by: Matthaei, Stephan, et al.
Published: (2012)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
by: Inagaki, Nobuya, et al.
Published: (2011)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
by: Wolffenbuttel, B. H. R., et al.
Published: (2016)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
by: Rosenstock, Julio, et al.
Published: (2013)

Long-acting preparations of exenatide
by: Cai, Yunpeng, et al.
Published: (2013)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
by: Gaebler, Julia A, et al.
Published: (2012)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
by: Taylor, Kristin, et al.
Published: (2011)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
by: Pencek, R, et al.
Published: (2012)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
by: MacConell, Leigh, et al.
Published: (2013)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann, Katherine V, et al.
Published: (2014)

Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes
by: Grossman, Samuel S.
Published: (2014)

Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives
by: Deng, Wuquan, et al.
Published: (2015)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
by: MacConell, Leigh, et al.
Published: (2015)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Published: (2015)

Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies
by: McDonell, Amanda L, et al.
Published: (2015)

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks
by: Tatarkiewicz, K, et al.
Published: (2013)

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
by: Russell-Jones, David, et al.
Published: (2012)

Evaluation of the stability of exenatide in aqueous solutions
by: Al Assadi, Ali
Published: (2015)

Effect of renal impairment on the pharmacokinetics of exenatide
by: Linnebjerg, Helle, et al.
Published: (2007)

Evolution of Exenatide as a Diabetes Therapeutic
by: Bhavsar, Sunil, et al.
Published: (2013)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
by: Ciszek, Michał
Published: (2013)

Comparison of different dosing regimens (once weekly vs. twice weekly, and once weekly vs. once every two weeks) with epoetin delta in patients with chronic kidney disease: a randomized controlled trial
by: Macdougall, Iain C
Published: (2007)

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
by: Berg, J K, et al.
Published: (2011)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
by: Rosenstock, Julio, et al.
Published: (2012)